Related Experiment Videos
New fACEs to the renin-angiotensin system
Ingrid Fleming1, Karin Kohlstedt, Rudi Busse
1Vascular Signaling Group, Institut für Kardiovaskuläre Physiologie, Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany. fleming@em.uni-frankfurt.de
Physiology (Bethesda, Md.)
|March 18, 2005
Summary
Inhibiting angiotensin-converting enzyme (ACE) benefits cardiovascular health. New findings show ACE inhibitors may work through a separate signaling pathway, not just by altering angiotensin II and bradykinin.
Area of Science:
- Cardiovascular Science
- Renal Physiology
- Enzymology
Background:
- Angiotensin-converting enzyme (ACE) inhibition is a cornerstone therapy for cardiovascular diseases.
- The precise mechanisms underlying ACE inhibitor efficacy are still under investigation.
- ACE2, an ACE homolog, is recognized for its role in cardiac and renal regulation.
Purpose of the Study:
- To explore the signaling pathways activated by ACE inhibitors beyond traditional angiotensin II and bradykinin modulation.
- To elucidate the role of ACE homologs, such as ACE2, in cardiovascular and renal homeostasis.
Main Methods:
- Review of recent evidence on ACE inhibitor mechanisms.
- Analysis of signaling cascades associated with ACE inhibition.
- Examination of the physiological roles of ACE and ACE2 in cardiovascular and renal systems.
Main Results:
- Evidence suggests ACE inhibitors activate distinct signaling cascades.
- These pathways may contribute significantly to the cardioprotective effects of ACE inhibitors.
- ACE2 plays a critical role in regulating heart and kidney function.
Conclusions:
- The beneficial effects of ACE inhibitors may involve novel signaling pathways.
- Understanding these pathways could lead to improved therapeutic strategies for cardiovascular and kidney diseases.
- ACE2 is a key regulator of cardiovascular and renal health.